We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Methadone Maintenance Treatment and Smoking Cessation (MMTASC)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified May 2009 by Vancouver Coastal Health.
Recruitment status was:  Enrolling by invitation
Sponsor:
ClinicalTrials.gov Identifier:
NCT00906386
First Posted: May 21, 2009
Last Update Posted: March 2, 2010
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
British Columbia Centre of Excellence for Women's Health
Information provided by:
Vancouver Coastal Health
  Purpose

The main hypotheses guiding the study are:

  1. Stable methadone maintenance patients receiving varenicline will be more likely to maintain abstinence than patients receiving placebo
  2. There will be no differences in the type and number of symptoms reported between stable methadone maintenance patients receiving varenicline and placebo
  3. There will be no changes in methadone dosage between abstinent and non-abstinent smokers
  4. There will be no differences in efficacy, withdrawal symptoms, and safety of varenicline between male and female participants

Condition Intervention Phase
Smoking Drug: Varenicline Drug: placebo Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: An Examination of the Efficacy, Safety, and Gender Differences in Using Varenicline as an Aid to Smoking Cessation in a Population of Methadone Maintained Opioid Dependent Patients (Pilot Trial)

Resource links provided by NLM:


Further study details as provided by Vancouver Coastal Health:

Primary Outcome Measures:
  • 7-day point prevalence of abstinence, 9-12 week continuous abstinence, 9-26 week continuous abstinence [ Time Frame: 9-12 weeks; 9-26 ]

Secondary Outcome Measures:
  • Sex differences in the efficacy, withdrawal symptoms, and safety of varenicline [ Time Frame: week 26 ]

Estimated Enrollment: 112
Study Start Date: May 2009
Estimated Study Completion Date: February 2011
Estimated Primary Completion Date: October 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Drug: Varenicline
oral, 1 mg twice daily, 12 weeks
Other Name: Champix, Chantix
Placebo Comparator: placebo Drug: placebo
oral, 1 mg twice daily, 12 weeks

Detailed Description:
  1. PURPOSE: The purpose of this placebo controlled study is to determine the efficacy, safety, and gender differences in using varenicline for smoking cessation in a population of stable methadone maintenance patients being treated for Opioid Dependence.
  2. HYPOTHESIS:

1.Stable methadone maintenance patients receiving varenicline will be more likely to maintain abstinence than patients receiving placebo 2.There will be no differences in the type and number of symptoms reported between stable methadone maintenance patients receiving varenicline and placebo 3.There will be no changes in methadone dosage between abstinent and non-abstinent smokers 4.There will be no differences in efficacy, withdrawal symptoms, and safety of varenicline between male and female participants

3. JUSTIFICATION: Patients on methadone maintenance treatment have smoking prevalence rates of up 80-90% and consequently disproportionately high mortality compared to the general population. A majority of these patients express a desire to quit but are generally more heavily dependent on nicotine. Randomized controlled trials in non-drug using populations have shown varenicline to be more efficacious for smoking cessation than placebo and other smoking cessation medications. This placebo controlled research protocol will examine varenicline's effect on smoking cessation/reduction and potential sex and gender differences in a population of methadone maintained patients.

4. OBJECTIVES:

Primary outcome:

  • Continuous abstinence from smoking during the last 4 weeks of treatment (weeks 9-12).

Secondary outcomes:

  • 7-day point prevalence of abstinence
  • Continuous abstinence Weeks 9-26
  • Sex and gender differences
  • Psychological assessment (Beck Depression Inventory)
  • Adverse effects (Nausea, Dry mouth, Flatulence, Constipation, Insomnia, -Abnormal dreams, Irritability, Sleep disorder, Headaches, Dizziness e.t.c.)

    5. RESEARCH METHOD: This pilot randomized, double-blind, placebo-controlled trial will be conducted at Vancouver Coastal Health Tobacco Dependence Clinic Vancouver, BC with a 12-week treatment period and follow-up of smoking status to week 26. The intervention will include the use of Varenicline titrated to 1 mg twice daily or placebo for 12 weeks, plus weekly brief smoking cessation counseling.

    6. All significance tests will be 2-tailed with an overall level of significance of a = 0.05. The primary outcome will be the analysis of continuous abstinence using a logistic regression model. The secondary outcomes will be:

    1. the analysis of 7-day abstinence and 9-26 week continuous abstinence using logistic regression analysis.
    2. Minnesota Nicotine Withdrawal Scale, Beck's Depression Inventory, and changes in methadone dose outcome using repeated measures analysis, and
    3. Chi-square tests and t-tests (or Mann-Whitney U) to determine sex and gender differences (male vs female) as well as differences in adverse effects of treatment (varenicline vs placebo)
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   19 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Stable on methadone maintenance (an individual is considered 'stable' if they have had a 4 week constant/fixed dose of methadone by self report and verified by B.C. Pharmanet review)
  • Subjects must have smoked at least 10 cigarettes per day during the past year and over the month prior to the screening visit, with no period of abstinence greater than 3 months in the past year
  • Ages 19 to 75 years (inclusive) and motivated to quit smoking
  • Should read and understand English
  • For female subjects:

    • instructed and agrees to avoid pregnancy through 30 days after the last dose of study medication
    • has a negative urine pregnancy test at screening
    • agrees to use birth control method(s) for duration of the study
  • Should be available by telephone

Exclusion Criteria:

  • Subjects who have used varenicline previously or are currently on other Nicotine Replacement Therapy or pharmacotherapy for smoking cessation (e.g., nicotine patch, zyban or wellbutrin)
  • Subjects who have a prior or current history of depression, bipolar affective disorder or a prior or current history of psychotic episodes or suicidal ideation (on the basis of self-report augmented by medical chart review where appropriate and/or corroborating history with previous or current health care provider)
  • Subjects who have not reached a stable dose of methadone in their methadone maintenance therapy (4 weeks at a constant/fixed dose of methadone by self-report and verified by B.C. Pharmanet review)
  • Pregnancy or currently nursing
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00906386


Locations
Canada, British Columbia
Three Bridges Community Health Centre
Vancouver, British Columbia, Canada, V6Z 1W2
Sponsors and Collaborators
Vancouver Coastal Health
British Columbia Centre of Excellence for Women's Health
  More Information

Responsible Party: Dr. Milan Khara, Clinical Director, Tobacco Dependence Clinic, Tobacco Dependence Clinic
ClinicalTrials.gov Identifier: NCT00906386     History of Changes
Other Study ID Numbers: 60409
First Submitted: May 15, 2009
First Posted: May 21, 2009
Last Update Posted: March 2, 2010
Last Verified: May 2009

Keywords provided by Vancouver Coastal Health:
Varenicline

Additional relevant MeSH terms:
Varenicline
Methadone
Nicotinic Agonists
Cholinergic Agonists
Cholinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Analgesics, Opioid
Narcotics
Central Nervous System Depressants
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Antitussive Agents
Respiratory System Agents